CCRP Exam Terms

Card Set Information

Author:
rivkawf
ID:
308850
Filename:
CCRP Exam Terms
Updated:
2015-10-01 16:16:47
Tags:
CCRP
Folders:

Description:
Terms used for the CCRP Certification Exam
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user rivkawf on FreezingBlue Flashcards. What would you like to do?


  1. Adverse Drug Reaction (ADR): Pre-approval
    All noxious and unintended responses to a medicinal product related to any dose. [causal relationship between med. product and adverse event cannot be ruled out]
  2. Adverse Drug Reaction (ADR): Marketed Product
    Response to drug which is noxious and unintended and which occurs at doses normally used for prophylaxis, diagnosis or therapy or for modification of physical function.
  3. Adverse Event (AE)
    Untoward medical occurrence in a patient or clinical trial subject administered a pharmaceutical product which does NOT necessarily have a causal relationship with this treatment. IE sign symptom just temporally associated with the use of an IP
  4. Contract Research Organization (CRO)
    Person/ organization contracted by Sponsor to perform Sponsor's duties
  5. Documentation
    All records that describe or record the methods, conduct, and/or results of a trial, factors affecting trial and actions taken
  6. ICH
    International Conference on Harmonisation
  7. Essential Documents
    Documents that permit the evaluation of the conduct of a study and quality of the data produced
  8. Independent Data-Monitoring Committee (IDMC)
    May be established by the Sponsor to assess the progress of clinical trial, safety data, efficacy endpoints, recommend to sponsor to continue, modify or stop trial
  9. Independent Ethics Committee (IEC)
    Independent body constituted of medical and non-med. members that ensures the protection of the rights, safety and well being of human subjects involved in a trial and to provide public assurance of that protection by reviewing/approving the trial protocol, suitability of investigators, facilities, and methods/materials used to obtain informed consent.
  10. Investigational Product
    Pharmaceutical form of active ingredient or placebo tested or used as ref. in clinical trail. This includes a product with marketing authorization when used/assembled in a way diff. from the approved form, when used for an unapproved indication, or used to gain further info about an approved use.
  11. Investigator
    Responsible for the conduct of a clinical trial at the trial site. If done by a team, they are the responsible leader of the team.
  12. Protocol
    Describes the objectives, design, methodology, stat considerations, and organization of the trial. Usually also gives background and rationale for the trial, but these can be in other referenced documents. Refers to the amendments as well.
  13. Quality Assurance (QA)
    planned/systematic actions established to ensure the trial is performed and the data generated in compliance w/ GCP and reg. requirements
  14. Quality Control (QC)
    Operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial related activities have been fulfilled.
  15. Regulatory Authorities
    Personnel that review submitted clinical data and those that conduct inspections. AKA "competent authorities"
  16. Serious (AE) or (ADR)
    • Any medical occurrence that at any dose
    • -results in death
    • -is life-threatening
    • -requires inpatient hospitalization or prolonged hospital stay
    • -results in persistent or sig. disability/incapacity
    • -is a congenital anomaly/birth defect
  17. Source Data
    Information in original records and certified copies of original records of clinical findings in a clinical trial necessary for the reconstruction and evaluation of the trial. Found in source documents.
  18. Source Documents
    Original doc. data and records (eg. lab notes, memoranda, subject diaries, pharmacy dispensing records, photographic negatives etc.)
  19. Standard Operating Procedure (SOP)
    Detailed written instructions to achieve uniformity of the performance of a specific function
  20. Unexpected ADR
    Adverse reaction the nature/severity of which is not consistent with the applicable product information.
  21. Vulnerable Subjects
    • members of group with hierarchical structure (medical, pharmacy, dental, nursing)
    • subordinates of the hosp./lab personnel
    • employees of pharm. industry
    • members of armed forces, people in detention
    • others: pts with incurable diseases, people in nursing homes, unemployed/ impoverished people, pts in emergency situations, ethnic minority groups, homeless, nomads, refugees, minors and those incapable of giving consent
  22. Parallel Group Design
    most common confirmatory trial, randomized to one of two or more treatment arms. IP at one or more dose vs. control/active comparator
  23. Crossover Design
    Randomized to a sequence of two or more treatments, subject acts as own control. Concern: carryover, disease should be stable and chronic before start
  24. Factorial Design
    Two or more treatments evaluated simultaneously through combinations of treatments (ex. A +B, A alone, B alone, no A or B) used to examine interaction of A and B, or to establish dose + response characteristics of use of A + B
  25. Inspection
    Act by reg. authorities of conducting a review of documents, facilities, records, and other resources deemed related to clinical trial that may be located at site, at Sponsor or other appropriate establishments
  26. Audit
    Systematic and independent examination of trial related activities and documents to determine whether the evaluated trail related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, GCP, SOPs, and applicable reg. requirements.
  27. Audit Report
    Written evaluation by sponsor's auditor of the results of the audit
  28. Audit Certificate
    Declaration of confirmation by the auditor that an audit has taken place
  29. Audit Trail
    Documentation that allows reconstruction of the course of events
  30. Non-clinical Trial
    not performed on human subjects
  31. Double-dummy
    Retain blind when administering supplies, when two treatments can't be made identical. Supplies are made for treatment A (active and placebo) and treatment B (active and placebo). Subjects take two sets of treatment; either A (active) and B (placebo), or A (placebo) and B (active).
  32. Equivalence Trial
    Response to two or more treatments differ by amount clinically unimportant
  33. Full Analysis Set
    Set of subjects close as possible to the ideal implied by the intention-to-treat principle
  34. Global Assessment Variable
    Objective variables + the Investigator's overall impression
  35. Intention-to-Treat Principle
    Subjects in treatment group should be followed up/assessed as members of that group regardless of compliance to course of treatment. Idea that effect of treatment is best assessed by evaluation on basis of intention to treat subject rather than actual treatment given.
  36. Interaction
    When difference between IP and control is dependent on another factor (i.e. site). Can be qualitative and quantitative
  37. Meta-Analysis
    Quantitative evidence from two or more studies about the same question
  38. Non-Inferiority Trial
    Response to IP is not clinically inferior to comparator (placebo or active control)
  39. Included Term
    In a hierarchical medical dictionary, the lowest level of dictionary term to which the investigator description is coded. ex. "joint pain"
  40. Preferred Term
    In a hierarchical medical dictionary, the level of grouping of included terms typically used in reporting frequency of occurrence.  ex. "arthralgia"
  41. Per Protocol Set (Valid Cases, Efficacy Sample, Evaluable Subjects Sample)
    set of data generated by subjects who followed protocol sufficiently to ensure these data would likely exhibit effects of treatment. Compliance covers such things as exposure to treatment, availability of measurements and absence of protocol violations.
  42. Superiority Trial
    Showing a response to an IP is superior to a comparator
  43. Surrogate Variable
    Indirect measure of effect where direct measurement is not feasible
  44. Treatment Emergent
    Event that emerges during treatment having been absent pre-treatment, or worsens relative to pre-treatment state

What would you like to do?

Home > Flashcards > Print Preview